Jump to main content
eTG Complete
eTG Complete
Index
  1. Home
  2. Rheumatology
  3. Rheumatoid arthritis
  4. Pharmacological management for rheumatoid arthritis
  5. Biological and targeted-synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for management of rheumatoid arthritis
  • Rheumatology
    • Assessment and initial management of musculoskeletal symptoms
    • Practical information on drugs used for musculoskeletal and rheumatological conditions
    • Adult-onset Still disease
    • Antiphospholipid syndrome
    • Autoinflammatory periodic fever syndromes
    • Back pain
    • Behçet syndrome
    • Crystal diseases including gout
    • Fibromyalgia
    • Idiopathic inflammatory myopathies
    • Immunoglobulin G4-related disease
    • Inflammatory connective tissue diseases
    • Juvenile idiopathic arthritis
    • Overview of limb conditions
    • Upper limb conditions
    • Lower limb conditions
    • Neck pain
    • Osteoarthritis
    • Musculoskeletal conditions in children and adolescents
    • Polymyalgia rheumatica
    • Pregnancy-related low back pain and pelvic pain
    • Raynaud phenomenon
    • Rheumatoid arthritis
      • Overview of rheumatoid arthritis
      • Diagnosis of rheumatoid arthritis
      • Management for rheumatoid arthritis
      • Pharmacological management for rheumatoid arthritis
        • Induction and maintenance of clinical remission in rheumatoid arthritis
        • Using a ‘treat-to-target’ approach aiming for clinical remission in rheumatoid arthritis
        • Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for treatment of rheumatoid arthritis
        • Systemic corticosteroids for management of rheumatoid arthritis
        • Biological and targeted-synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for management of rheumatoid arthritis
          • Overview of biological and targeted-synthetic disease modifying antirheumatic drugs for rheumatoid arthritis
          • Biological DMARDs (bDMARDs) for rheumatoid arthritis
          • Targeted synthetic DMARDs (tsDMARDs) for rheumatoid arthritis
          • Perioperative use of b/tsDMARDs
          • Dose reduction and discontinuation of b/tsDMARDs
      • Monitoring disease activity in rheumatoid arthritis
      • Pain management in rheumatoid arthritis
      • Management for comorbidities associated with rheumatoid arthritis
      • Monitor for adverse effects of drug therapy
      • Stopping tobacco smoking in patients with rheumatoid arthritis
      • Management for fatigue associated with rheumatoid arthritis
      • Physical activity and exercise for patients with rheumatoid arthritis
      • Diet for patients with rheumatoid arthritis
      • References
    • Spondyloarthritis
    • Systemic vasculitides
    • Transition of adolescents to adult rheumatology management
    • Viral arthritis

Biological and targeted-synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for management of rheumatoid arthritis

Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC), 2023Smolen, 2020

  • Overview of biological and targeted-synthetic disease modifying antirheumatic drugs for rheumatoid arthritis
  • Biological DMARDs (bDMARDs) for rheumatoid arthritis
  • Targeted synthetic DMARDs (tsDMARDs) for rheumatoid arthritis
  • Perioperative use of b/tsDMARDs
  • Dose reduction and discontinuation of b/tsDMARDs
  • Contact us
  • Conditions of use and disclaimer
  • Privacy policy
  • Copyright permission
  • Support and FAQ

www.tg.org.au
All site content © Therapeutic Guidelines Limited 2020. Therapeutic Guidelines Limited, Ground Floor, 473 Victoria Street, West Melbourne, Victoria 3003, Australia © Therapeutic Guidelines Ltd (eTG August 2020)

Created: No created attribute found. Modified: No revised attribute found. (HW Diagnostics)